By Chris Wack

Lexicon Pharmaceuticals Inc. (LXRX) said NASDAQ has halted trading of the company's common stock because the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee is meeting Thursday to review Lexicon collaborator Sanofi's New Drug Application for sotagliflozin, an investigational oral treatment for adults with type 1 diabetes.

The biopharmaceutical company said the Prescription Drug User Fee Act date for completion of the review of the New Drug Application for sotagliflozin is anticipated to be March 22, 2019.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 17, 2019 07:30 ET (12:30 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.